Rising Logistics and Raw Material Procurement Costs During the COVID-19 Pandemic
First written in FY2022-Q3. 5 of 12 entries say "Restated". Latest entry: 2026-07-30.
Eiken Chemical moved to the "Worse" side of this theme in 2022, the same year as the typical company in this theme.
The whole theme swung hardest in 2019: 10 of 16 companies on the "Worse" side.
10 other companies' latest entry also says "Restated".
- FY2026WorsenedAnnual report
「If the prices concerned rise sharply for these or other reasons, or if the US-Iran war is prolonged and energy prices remain high, the cost of the products may increase, potentially affecting our financial position and operating results.」
In addition to the risk of higher raw-material, transportation and foreign exchange costs, the company identified prolonged high energy prices resulting from an extended US-Iran war as a specific factor that could increase product costs. - FY2026-H1RestatedAnnual report
「In the clinical laboratory testing industry, the business environment has become increasingly challenging due to continued increases in logistics and raw-material procurement costs, as well as measures to contain healthcare costs.」
The company continues to state that logistics and raw-material procurement costs and other costs remain elevated. - FY2025WorsenedAnnual report
「The prices of raw materials used in our group's products fluctuate due to changes in economic conditions in each country and region, market prices associated with pandemics and geopolitical risks, fuel costs, foreign exchange rates and other factors. If these prices rise sharply for such reasons, or if transportation costs for the products rise sharply, the cost of the products may increase, potentially affecting our financial position and operating results.」
The previously recognized cost increases in the industry environment were separately specified as the risk of higher product costs resulting from sharp increases in raw-material prices, fuel costs, foreign exchange and transportation costs. - FY2024-Q2WorsenedAnnual report
「In the clinical laboratory testing industry, the business environment has become increasingly challenging due to measures to contain healthcare costs and higher logistics and raw-material procurement costs resulting from the weaker yen and higher crude oil prices. Companies are consequently required to improve their cost competitiveness and expand overseas operations proactively.」
In addition to the previously cited increases in resource, logistics and raw-material procurement costs, the weaker yen and higher crude oil prices were explicitly identified, making the factors behind the deterioration of the industry's business environment from rising costs more specific. - FY2024-Q1RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher costs for resources, logistics, and raw-material procurement, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to recognize that the industry's business environment is challenging due to higher resource, logistics and raw-material procurement costs. - FY2023-Q3RestatedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher costs for resources, logistics, and raw-material procurement during the COVID-19 pandemic, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
The company continues to recognize that the industry's business environment is challenging due to higher resource, logistics and raw-material procurement costs. - FY2023-Q2WorsenedAnnual report
「In the clinical diagnostics industry, the operating environment has become even more challenging due to healthcare cost-containment measures and higher costs for resources, logistics, and raw-material procurement during the COVID-19 pandemic, requiring companies to further strengthen their cost competitiveness and actively expand overseas.」
In addition to the previously cited increases in logistics and raw-material procurement costs, resource costs were explicitly identified, and the company stated that cost increases during the COVID-19 pandemic had made the industry's business environment increasingly challenging. - FY2023-Q1RestatedAnnual report
「In the clinical laboratory testing industry, the business environment has become increasingly challenging due to measures to contain healthcare costs and higher logistics and raw-material procurement costs during the COVID-19 pandemic,」
The company continues to state that higher logistics and raw-material procurement costs are factors making the industry's business environment challenging. - FY2022MaterialisedAnnual report
「In the clinical laboratory testing industry, the business environment has become increasingly challenging due to measures to contain healthcare costs and higher logistics and raw-material procurement costs during the COVID-19 pandemic,」
Higher logistics and raw-material procurement costs were actually cited as factors making the industry's business environment increasingly challenging. - FY2022-Q3First statedAnnual report
「In the clinical laboratory testing industry, the business environment has become increasingly challenging due to measures to contain healthcare costs and higher logistics and raw-material procurement costs during the COVID-19 pandemic,」
Higher logistics and raw-material procurement costs during the COVID-19 pandemic were identified independently for the first time as factors making the business environment in the clinical laboratory testing industry more challenging.